Programmed Death–Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC

In non-metastatic non-small-cell lung cancer (NSCLC), outcomes remain poor. Adjuvant chemotherapies provide a limited improvement in disease-free survival. Recent exploratory studies on early-stage NSCLC show that immunotherapy given according to Programmed Death–Ligand 1 expression generates variab...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancers (Basel)
Main Authors: Ancel, Julien, Birembaut, Philippe, Dewolf, Maxime, Durlach, Anne, Nawrocki-Raby, Béatrice, Dalstein, Véronique, Delepine, Gonzague, Blacher, Silvia, Deslée, Gaëtan, Gilles, Christine, Polette, Myriam
格式: Artigo
語言:Inglês
出版: MDPI 2019
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6826860/
https://ncbi.nlm.nih.gov/pubmed/31546725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11101411
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍